Skip to main content
. Author manuscript; available in PMC: 2021 Oct 5.
Published in final edited form as: Clin Cancer Res. 2021 Jan 8;27(18):5038–5048. doi: 10.1158/1078-0432.CCR-20-3241

Table 4.

Longitudinal reference standards used by CIMAC-CIDC

Reference material Description Amount used Frequency of testing
CyTOF BioLegend PBMCs 1:1 mixture of dual-labeled activated and resting PBMC Veri-Cells 200–350 vials (1 million cells per vial) Spiked into every clinical sample at 10 % volume
Olink Various • Pooled plasma from healthy donors
• Randox cytokine cocktail
• Olink experimental controls
Over 1,000 aliquots available Used in every run
ELISA Grand Serology Healthy Plasma Pools • Healthy-donor plasma pools as negative control and titer calculations
• Positive plasma pools from patients with reactivity to several antigens
Over 300 mL of plasma available (3–15 µl per assay) Used as appropriate
IHC/IF MIBI CHTN Master TMA Master Tissue MicroArray (TMA) containing normal, neoplastic, and tumor tissue Sequential sections will be distributed by CHTN (four TMAs blocks) Twice per year
WES Coriell Institute HapMap Cell Line Pool • Two pools of 10 HapMap cell lines containing different allele fractions.
• Two cell lines as germline controls
Cell-line pellets embedded into FFPE blocks, extracted DNA distributed to each site Twice per year Used as analysis pipelines develop over time
Microbiome Various • Healthy donor fecal samples (RefA)
• ZymoBIOMICS Microbial Community Standard (RefB)
• DNA library of gut-relevant microbes of known abundance (RefC)
• RefA: 60 ready-to-use aliquots from ~100 mg of material
• RefB: commercially available
Used to control biases and batch effects for extractions, library prep, and sequencing runs

CHTN: Cooperative Human Tissue Network